Migraine: Triptan responders are more likely to respond to erenumab

Key clinical point: Patients with migraine who showed a favorable response to at least one triptan had a higher likelihood to respond to erenumab treatment than those not responding to triptans.

Major finding: Triptan responders had higher odds for responding to erenumab treatment than the triptan nonresponders (odds ratio, 3.64; P = .014).

Study details: Findings are from an ancillary study from a real-life observational study involving 140 patients with migraine treated with erenumab for at least 6 months.

Disclosures: The publication fee was unconditionally granted by Novartis Farma S.r.l. The lead author along with some other authors declared no competing interests. Some authors declared financial and nonfinancial relationships with various pharmaceutical sources such as Eli Lilly, Novartis, Allergan, Teva, Abbott, Innovet Italia Srl, Epitech Group, and Lusofarmaco.

Source:Frattale I et al. J Headache Pain. 2021 Jan 6. doi: 10.1186/s10194-020-01213-3.

Key clinical point: Patients with migraine who showed a favorable response to at least one triptan had a higher likelihood to respond to erenumab treatment than those not responding to triptans.

Major finding: Triptan responders had higher odds for responding to erenumab treatment than the triptan nonresponders (odds ratio, 3.64; P = .014).

Study details: Findings are from an ancillary study from a real-life observational study involving 140 patients with migraine treated with erenumab for at least 6 months.

Disclosures: The publication fee was unconditionally granted by Novartis Farma S.r.l. The lead author along with some other authors declared no competing interests. Some authors declared financial and nonfinancial relationships with various pharmaceutical sources such as Eli Lilly, Novartis, Allergan, Teva, Abbott, Innovet Italia Srl, Epitech Group, and Lusofarmaco.

Source:Frattale I et al. J Headache Pain. 2021 Jan 6. doi: 10.1186/s10194-020-01213-3.

Key clinical point: Patients with migraine who showed a favorable response to at least one triptan had a higher likelihood to respond to erenumab treatment than those not responding to triptans.

Major finding: Triptan responders had higher odds for responding to erenumab treatment than the triptan nonresponders (odds ratio, 3.64; P = .014).

Study details: Findings are from an ancillary study from a real-life observational study involving 140 patients with migraine treated with erenumab for at least 6 months.

Disclosures: The publication fee was unconditionally granted by Novartis Farma S.r.l. The lead author along with some other authors declared no competing interests. Some authors declared financial and nonfinancial relationships with various pharmaceutical sources such as Eli Lilly, Novartis, Allergan, Teva, Abbott, Innovet Italia Srl, Epitech Group, and Lusofarmaco.

Source:Frattale I et al. J Headache Pain. 2021 Jan 6. doi: 10.1186/s10194-020-01213-3.